Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders

Abstract

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

1 . (canceled) 
     
     
         2 . A pharmaceutical composition comprising eszopiclone, or a pharmaceutically acceptable salt, solvate, clathrate, polymorph, or co-crystal thereof, and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, or a pharmaceutically acceptable salt, solvate, clathrate, polymorph, or co-crystal thereof. 
     
     
         3 - 25 . (canceled) 
     
     
         26 . A method of treating a patient suffering from a CNS disorder of Axis I, comprising the step of co-administering to a patient in need thereof a therapeutically effective amount of eszopiclone, and a therapeutically effective amount of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, or a pharmaceutically acceptable salt of either. 
     
     
         27 . The method according to  claim 26 , wherein the CNS disorder of Axis I is selected from attention deficit disorder (ADD) and attention deficit/hyperactivity disorder (ADHD). 
     
     
         28 . The method according to  claim 27 , wherein the CNS disorder of Axis I is attention deficit/hyperactivity disorder (ADHD).